• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Single-dose carboplatin is effective against testicular cancer

Article

Scientists in the United Kingdom report that a single dose of carboplatin (Paraplatin) after surgery for early testicular cancer is as safe and effective as 2 to 3 weeks of radiotherapy after surgery, with less toxicity, and with durable results.

Scientists in the United Kingdom report that a single dose of carboplatin (Paraplatin) after surgery for early testicular cancer is as safe and effective as 2 to 3 weeks of radiotherapy after surgery, with less toxicity, and with durable results.

The multicenter, international study of 1,477 patients with stage 1 seminoma, found similar rates of relapse-free survival 3 years after treatment: 94.8% in those who received carboplatin and 95.9% in those treated with the standard 3 weeks of radiation therapy (The Lancet 2005; 366:293-300). However, patients in the carboplatin group had fewer toxic effects and returned to work sooner than those in the radiation group. The single-dose chemotherapy also is more convenient than radiation therapy for patients, the authors said.

Five years after treatment, patients in the carboplatin group had 72% fewer tumors of the same type in the other testicle, reported lead researcher Tim Oliver, MD, of Barts and The London Queen Mary's School of Medicine and Dentistry.

"We may be able to reduce the necessity of taking the whole testicle," Dr. Oliver told HealthDay News.

Related Videos
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Woman talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Zhina Sadeghi, MD, answers a question during a video interview
A panel of 4 experts on prostate cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.